Previous Close | 146.28 |
Open | 147.05 |
Bid | 149.92 x 100 |
Ask | 150.74 x 100 |
Day's Range | 145.11 - 150.40 |
52 Week Range | 110.74 - 159.52 |
Volume | |
Avg. Volume | 102,277 |
Market Cap | 4.876B |
Beta (5Y Monthly) | 0.70 |
PE Ratio (TTM) | 44.90 |
EPS (TTM) | 3.35 |
Earnings Date | Jul 26, 2024 - Jul 30, 2024 |
Forward Dividend & Yield | 0.79 (0.54%) |
Ex-Dividend Date | Dec 26, 2023 |
1y Target Est | 154.33 |
Comprehensive Analysis of Balchem's Financial Performance and Strategic Highlights
MONTVALE, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2024 fiscal first quarter ended March 31, 2024. The Company reported quarterly net sales of $239.7 million, quarterly net earnings of $29.0 million, adjusted EBITDA(a) of $60.9 million, and free cash flow(a) of $26.8 million. Ted Harris, Chairman, President and CEO of Balchem said, "The first quarter was a very good start to the year for Balchem. We delivered record net sa
First Professional Sports Partnership for VitaCholine® encompasses rights across regions including the United States and the United Kingdom.MONTVALE, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- The New York Jets announced a partnership with VitaCholine, a Balchem Human Nutrition and Health brand of the essential nutrient choline, as Proud Partner of the team. This agreement marks VitaCholine’s first sponsorship and the first sponsorship in the Nutritional Ingredient category of a major professional s